PolyPid (PYPD)

• Market cap: $21.9M
• 1 day: -8.00%
• 5 days: 22.90%
• 1 month: -7.74%
• 3 months: -6.94%
• 6 months: -19.50%
• Year to date: -40.92%
• 1 year: -18.07%
• 5 years: -99.44%
• 10 years: -99.44%

About: PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.

Employees: 62

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

33% more funds holding

Funds holding: 9 [Q2] → 12 (+3) [Q3]

28% more capital invested

Capital invested by funds: $5.19M [Q2] → $6.64M (+$1.46M) [Q3]

14.88% more ownership

Funds ownership: 25.17% [Q2] → 40.05% (+14.88%) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $10 211% upside
• Avg. target: $12 273% upside
• High target: $14 335% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju 39% 1-year accuracy 121 / 308 met price target	335% upside $14	Buy Reiterated	16 Dec 2024
Craig-Hallum Chase Knickerbocker 43% 1-year accuracy 10 / 23 met price target	211% upside $10	Buy Initiated	4 Nov 2024